4.8 Article

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Journal

CELL
Volume 182, Issue 5, Pages 1232-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2020.07.017

Keywords

-

Funding

  1. NIH/NCI [R01CA227807, U54CA224081, R01CA204302, R01CA211052, R01CA231300, R01CA169338, U01CA217882]
  2. Van Auken Foundation
  3. Novartis Pharmaceuticals
  4. Pfizer
  5. University of California Cancer League (United States)
  6. Damon Runyon Cancer Research Foundation [P0528804]
  7. Doris Duke Charitable Foundation [P2018110]
  8. V Foundation [P0530519]
  9. Mildred Scheel postdoctoral fellowship fromthe German Cancer Aid
  10. NHLBI [T32 HL007185]
  11. AstraZeneca (United Kingdom)
  12. [K12 CA086913]

Ask authors/readers for more resources

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA sequencing (scRNA-seq) of metastatic lung cancer was performed using 49 clinical biopsies obtained from 30 patients before and during targeted therapy. Over 20,000 cancer and tumor microenvironment (TME) single-cell profiles exposed a rich and dynamic tumor ecosystem. scRNA-seq of cancer cells illuminated targetable oncogenes beyond those detected clinically. Cancer cells surviving therapy as residual disease (RD) expressed an alveolar-regenerative cell signature suggesting a therapy-induced primitive cell-state transition, whereas those present at on-therapy progressive disease (PD) upregulated kynurenine, plasminogen, and gap-junction pathways. Active T-lymphocytes and decreased macrophages were present at RD and immunosuppressive cell states characterized PD. Biological features revealed by scRNA-seq were biomarkers of clinical outcomes in independent cohorts. This study highlights how therapy-induced adaptation of the multi-cellular ecosystem of metastatic cancer shapes clinical outcomes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available